Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVEL trial of 177Lu-edotreotide versus everolimus in lung and thymic neuroendocrine tumors
2022-502154-13-00Phase 3Authorised
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Oct 2023
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in bronchial neuroendocrine tumor and thymic neuroendocrine carcinoma (TNEC) comparing 177Lu-edotreotide arm with everolimus arm (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2023; status: authorised.
02
Drugs
lutetium Lu 177-edotreotideeverolimus
03
Conditions
bronchial neuroendocrine tumorthymic neuroendocrine carcinoma (TNEC)
Beyond the preview
Go deeper on 2022-502154-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502154-13-00.